Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2024-12-12 Capital/Financing Update
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시) (제21회차 CB)
Capital/Financing Update Classification · 100% confidence The document is a 'Securities Issuance Result' (증권 발행결과) announcement regarding the issuance of convertible bonds (CB). It details the issuance method, amount, and payment date. This falls under the category of company financing activities and capital structure changes, which corresponds to the 'CAP' (Capital/Financing Update) classification.
2024-12-12 Korean
투자판단관련주요경영사항 ('어나프라주(오피란제린염산염)' 식품의약품안전처 품목허가 승인)
Regulatory Filings Classification · 100% confidence The document is a regulatory disclosure filed by Vivozon Pharmaceutical regarding the approval of a new drug ('Anapra Injection') by the Ministry of Food and Drug Safety. It is a formal announcement of a material business event (regulatory approval) rather than a financial report, audit, or presentation. Since it does not fit into specific categories like M&A, dividends, or share transactions, it falls under the general regulatory filing category.
2024-12-12 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) regarding the issuance of convertible bonds (전환사채권 발행결정) and a subsequent correction (정정신고) filed with the Korea Exchange (KRX). This type of filing is a standard regulatory disclosure for capital raising activities, specifically debt financing that can be converted into equity. It fits the 'Capital/Financing Update' category as it details the terms, interest rates, and purpose of the bond issuance.
2024-12-06 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from Vivozon Pharmaceutical, specifically detailing the decision to issue convertible bonds (전환사채권 발행결정). This type of filing is a standard regulatory disclosure in the Korean market regarding capital structure changes and financing activities. It provides specific terms of the bond issuance, such as interest rates, conversion prices, and maturity dates. Since it details a specific financing event rather than a general regulatory announcement or a report publication notice, it falls under the 'Capital/Financing Update' category.
2024-12-02 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders). This is a standard regulatory filing in South Korea (DART system) used by insiders (executives and major shareholders) to report changes in their shareholdings, including conversions of convertible bonds. This falls under the category of 'Director's Dealing' (DIRS) as it details personal/insider share transactions and ownership changes.
2024-11-19 Korean
[기재정정]전환청구권행사 (제19회차)
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing regarding the exercise of conversion rights (전환청구권행사) for convertible bonds (전환사채) by Vivozon Pharmaceutical. It details the number of shares issued, the conversion price, and the impact on total shares outstanding. This type of corporate action, involving changes to capital structure through the conversion of debt into equity, falls under the 'Share Issue/Capital Change' category.
2024-11-18 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.